CAMPBELL, Calif. , Dec. 11, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (the “ Company ”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “ Bankruptcy Court ”) on its Second Amended   Joint Prepackaged

CAMPBELL, Calif. , Nov. 13, 2020 (GLOBE NEWSWIRE) -- On November 10, 2020 , VIVUS, Inc. (the “ Company ”), a biopharmaceutical company, filed the Second Amended   Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (as may be amended,

CAMPBELL, Calif. , July 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“ IEH ”) will take 100% ownership of

CAMPBELL, Calif. , June 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma LLC ), which holds a principal amount

Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported financial results for the quarter ended March 31, 2020 and provided a business update.

CAMPBELL, Calif. , May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2020 after the market close on Wednesday, May 6, 2020 . The Company will host a conference call beginning at

CAMPBELL, Calif. , May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC , which holds a principal amount of  approximately $170.1 million of the Company’s Convertible

CAMPBELL, Calif. , April 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company’s common stock at a purchase price of $1.60 per

CAMPBELL, Calif. , April 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,218,750 shares of the

Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19 CAMPBELL, Calif. , March 31, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc.